Logo image of CTXR

CITIUS PHARMACEUTICALS INC (CTXR) Stock Fundamental Analysis

NASDAQ:CTXR - Nasdaq - US17322U2078 - Common Stock - Currency: USD

1.8  -0.05 (-2.7%)

After market: 1.78 -0.02 (-1.11%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CTXR. CTXR was compared to 193 industry peers in the Pharmaceuticals industry. CTXR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CTXR is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CTXR had negative earnings in the past year.
In the past year CTXR has reported a negative cash flow from operations.
In the past 5 years CTXR always reported negative net income.
CTXR had a negative operating cash flow in each of the past 5 years.
CTXR Yearly Net Income VS EBIT VS OCF VS FCFCTXR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

CTXR has a Return On Assets (-33.74%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -62.26%, CTXR is in line with its industry, outperforming 51.35% of the companies in the same industry.
Industry RankSector Rank
ROA -33.74%
ROE -62.26%
ROIC N/A
ROA(3y)-32.16%
ROA(5y)-30.75%
ROE(3y)-42.39%
ROE(5y)-39.56%
ROIC(3y)N/A
ROIC(5y)N/A
CTXR Yearly ROA, ROE, ROICCTXR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CTXR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTXR Yearly Profit, Operating, Gross MarginsCTXR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, CTXR has more shares outstanding
Compared to 5 years ago, CTXR has less shares outstanding
CTXR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CTXR Yearly Shares OutstandingCTXR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
CTXR Yearly Total Debt VS Total AssetsCTXR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

CTXR has an Altman-Z score of -3.71. This is a bad value and indicates that CTXR is not financially healthy and even has some risk of bankruptcy.
CTXR has a worse Altman-Z score (-3.71) than 62.16% of its industry peers.
CTXR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.71
ROIC/WACCN/A
WACCN/A
CTXR Yearly LT Debt VS Equity VS FCFCTXR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

CTXR has a Current Ratio of 0.41. This is a bad value and indicates that CTXR is not financially healthy enough and could expect problems in meeting its short term obligations.
CTXR has a Current ratio of 0.41. This is amonst the worse of the industry: CTXR underperforms 96.76% of its industry peers.
CTXR has a Quick Ratio of 0.41. This is a bad value and indicates that CTXR is not financially healthy enough and could expect problems in meeting its short term obligations.
CTXR has a worse Quick ratio (0.09) than 98.92% of its industry peers.
Industry RankSector Rank
Current Ratio 0.41
Quick Ratio 0.09
CTXR Yearly Current Assets VS Current LiabilitesCTXR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for CTXR have decreased strongly by -251.47% in the last year.
EPS 1Y (TTM)-251.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 24.16% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y57.36%
EPS Next 2Y52.13%
EPS Next 3Y37.12%
EPS Next 5Y24.16%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CTXR Yearly Revenue VS EstimatesCTXR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
CTXR Yearly EPS VS EstimatesCTXR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30 -40

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CTXR. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 1.30 indicates a rather cheap valuation of CTXR.
Based on the Price/Forward Earnings ratio, CTXR is valued cheaply inside the industry as 98.92% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of CTXR to the average of the S&P500 Index (22.70), we can say CTXR is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 1.3
CTXR Price Earnings VS Forward Price EarningsCTXR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTXR Per share dataCTXR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CTXR's earnings are expected to grow with 37.12% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.13%
EPS Next 3Y37.12%

More info and screens

0

5. Dividend

5.1 Amount

CTXR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CITIUS PHARMACEUTICALS INC

NASDAQ:CTXR (2/21/2025, 8:11:18 PM)

After market: 1.78 -0.02 (-1.11%)

1.8

-0.05 (-2.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-13 2025-02-13
Earnings (Next)05-12 2025-05-12
Inst Owners7.63%
Inst Owner Change-95.97%
Ins Owners5.74%
Ins Owner Change0%
Market Cap15.46M
Analysts82.22
Price Target8.67 (381.67%)
Short Float %6.34%
Short Ratio3.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.25%
PT rev (3m)82.14%
EPS NQ rev (1m)-140%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-167.96%
EPS NY rev (3m)-1068.42%
Revenue NQ rev (1m)-18.28%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-54.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1.3
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.24
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.4
EYN/A
EPS(NY)1.38
Fwd EY76.88%
FCF(TTM)-3.7
FCFYN/A
OCF(TTM)-3.12
OCFYN/A
SpS0
BVpS7.61
TBVpS-4.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.74%
ROE -62.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.16%
ROA(5y)-30.75%
ROE(3y)-42.39%
ROE(5y)-39.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.41
Quick Ratio 0.09
Altman-Z -3.71
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-251.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.2%
EPS Next Y57.36%
EPS Next 2Y52.13%
EPS Next 3Y37.12%
EPS Next 5Y24.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-9.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-11.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.09%
OCF growth 3YN/A
OCF growth 5YN/A